A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of ruxolitinib in patients with advanced polycythemia vera or essential thrombocythemia refractory to hydroxyurea.

Trial Profile

A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of ruxolitinib in patients with advanced polycythemia vera or essential thrombocythemia refractory to hydroxyurea.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 14 Jun 2015 Pooled safety analysis (NCT00726232, RELIEF and RESPONSE) results presented at the 20th Congress of the European Haematology Association.
    • 02 Jun 2015 Pooled safety analysis (This study, RELIEF and RESPONSE) results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 14 Apr 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top